Custom Web Apps & SaaS × Labs & DTC Diagnostics
Custom Web Apps & SaaS for Labs & DTC Diagnostics
Lab result portal software development — HL7 ORU ingest, physician review workflows, and white-label B2B portals built for diagnostic businesses.
Why this matters
Why labs & dtc diagnostics need custom web apps & saas built for them.
DTC diagnostics is a software business wearing a lab coat: the assay happens in a CLIA lab, but the customer experience — ordering, results, interpretation, follow-up — is entirely your application layer, and it is where brands win or lose.
Raw lab values without interpretation are a customer-service nightmare and a clinical-risk surface. Results portals need physician review workflows, reference-range context, and escalation paths for critical values — none of which come off the shelf.
We build the full diagnostic application stack: requisition generation, HL7 ORU result ingest from your lab partners, physician review queues, consumer-grade result presentation, and B2B white-label portals when you are ready to sell through partners.
Test availability is state law, not configuration whimsy: physician-order requirements and direct-access testing rules differ by state, and the platform has to enforce that map at checkout, not discover it in a complaint.
How we approach it
How Synaptis builds custom web apps & saas for labs & dtc diagnostics.
We architect diagnostic platforms around the result lifecycle: order placed, requisition issued, specimen tracked, result ingested, physician reviewed, customer notified, follow-up handled. Each stage gets real engineering — ORU feeds parsed into structured trendable data, review queues that let a physician network clear results efficiently with critical-value escalation, and result presentation that explains without overstepping into unlicensed practice. White-label architecture comes early if B2B is in your model, because retrofitting multi-tenancy is twice the work.
Compliance considerations
What the regulatory picture looks like.
DTC diagnostics operates inside an unusual regulatory lattice. CLIA governs the laboratory itself, but your platform inherits adjacent duties: results must be delivered in ways consistent with CLIA's patient-access provisions, and the physician-order layer — where licensed providers authorize testing — needs genuine clinical review, not rubber-stamp automation that state medical boards increasingly scrutinize. Direct-access testing rules vary sharply by state: some allow consumers to order most tests directly, others require physician orders for nearly everything, and your checkout must enforce that map per test, per state.
Results are PHI of a sensitive grade, requiring full HIPAA architecture — encryption, access controls, audit trails — plus careful design of the interpretation layer: explaining a result is service; diagnosing from it crosses into medical practice your platform must route to licensed providers. If you white-label to B2B partners, tenant isolation and per-partner BAA chains multiply the compliance surface. This is a general overview only; diagnostic companies should map their state-by-state posture with qualified regulatory counsel before launch.
Go deeper.
Capability deep-dive
Custom Web Apps & SaaS
Everything we ship under custom web apps & saas — outcomes, process, and use cases.
Explore capability →Industry deep-dive
Labs & DTC Diagnostics
How we work with labs & dtc diagnostics — common builds, compliance posture, and engagement models.
Explore industry →FAQ
Common questions.
How do results get from the lab into the platform?
Through HL7 ORU result feeds from your lab partners — Quest, Labcorp, or specialty labs — parsed into structured data, validated, and matched to orders automatically. Mapping each lab's feed quirks is real engineering work, which is why we build a normalization layer rather than per-lab spaghetti.
What does the physician review workflow look like?
A queue: results land with abnormality flags pre-computed, physicians review and release with annotations, and critical values escalate immediately by protocol. The design goal is clearing routine results in seconds while guaranteeing the abnormal ones get genuine attention — efficiency without rubber-stamping.
Can consumers in any state buy any test?
No — and the platform enforces it. Direct-access testing rules differ per state, so the catalog is state-aware: what a customer can order, and whether a physician order intermediates, is determined at checkout by their location. That enforcement being automatic is what keeps growth from outrunning compliance.
Do you build the white-label B2B side too?
Yes — multi-tenant architecture with per-partner branding, isolated data, partner-level reporting, and admin tooling. If B2B distribution is anywhere in your roadmap, the time to design for it is the original build; multi-tenancy retrofits are among the most painful projects in SaaS.
How do you present results without practicing medicine?
Carefully and deliberately: reference-range context, plain-language explanation of what a marker measures, trend visualization — and clear routing to licensed providers for interpretation that crosses into clinical judgment. We design that boundary with your medical leadership so it is principled, not accidental.
Let's scope custom web apps & saas for your labs & dtc diagnostic operation.
30-minute working session with a Synaptis architect. We'll discuss your specific workflows and map a build plan.